https://rijournals.com/biological-and-applied-science/

RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 4(1):11-15, 2024

©RIJBAS Publications ISSN: 1597-2879

https://doi.org/10.59298/RIJBAS/2024/411115

# Modulation of Innate Immunity via Pattern Recognition Receptors (PRRs) for Antiviral and Antitumor Therapies

**Bizimana Rukundo T.**

**Faculty of Biological Sciences Kampala International University Uganda**

## ABSTRACT

Pattern recognition receptors (PRRs) are vital components of the innate immune system, playing a crucial role in detecting pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). This review explores the modulation of innate immunity via PRRs for antiviral and antitumor therapies. PRRs, including toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-I-like receptors (RLRs), and C-type lectin receptors (CLRs), initiate immune responses that enhance the recognition and elimination of pathogens and tumor cells. TLRs, for instance, trigger pro-inflammatory cytokine production and activate dendritic cells, facilitating adaptive immune responses. The therapeutic potential of PRR agonists is significant; they can be used as standalone treatments or in combination with existing antiviral and cancer therapies. PRR agonists enhance vaccine efficacy, promote robust antiviral responses, and improve the recognition of tumor antigens. Additionally, oncolytic viruses can exploit PRR pathways to stimulate innate and adaptive immunity against tumors. However, challenges such as the risk of excessive inflammation and the need for targeted delivery of PRR agonists remain. Future research should focus on optimizing PRR-targeted strategies to harness their full therapeutic potential while minimizing adverse effects. This review highlights the promising role of PRRs in enhancing immune responses and discusses their implications for developing innovative antiviral and antitumor therapies.

**Keywords:** Pattern recognition receptors (PRRs), Innate immunity, Antiviral therapies, Antitumor therapies, Immune modulation

## INTRODUCTION

The innate immune system serves as the body's first line of defense against invading pathogens and tumor cells, employing a diverse array of mechanisms to detect and respond to these threats [1]. A critical component of this system is pattern recognition receptors (PRRs), which play a fundamental role in identifying pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) [2]. These receptors are essential for initiating the immune response, leading to the activation of both innate and adaptive immunity.

PRRs can be broadly classified into several families, including Toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-I-like receptors (RLRs), and C-type lectin receptors (CLRs)[3]. Each of these receptor types is specialized in recognizing distinct molecular patterns, enabling the immune system to mount appropriate responses to various pathogens, including bacteria, viruses, fungi, and cancer cells. For instance, TLRs, found on immune cells such as macrophages and dendritic cells, detect extracellular and endosomal PAMPs, leading to the activation of intracellular signaling pathways that promote the production of pro-inflammatory cytokines [4]. This process not only facilitates the immediate immune response but also plays a crucial role in shaping the adaptive immune response.

The modulation of innate immunity via PRRs has gained significant attention in recent years for its potential therapeutic applications in antiviral and antitumor therapies [5]. By harnessing the signaling capabilities of PRRs, researchers are exploring strategies to enhance immune responses against viral infections and tumors. For example, PRR agonists are being investigated as adjuvants in vaccines, where they can boost the immune response

and improve the efficacy of antiviral vaccines [6]. Additionally, the use of oncolytic viruses—viruses that selectively infect and kill cancer cells—exploits PRR pathways to stimulate robust immune responses against tumors.

Despite the promising potential of PRR modulation, several challenges remain, including understanding the complex interplay of different PRRs in various cellular contexts and the potential for adverse inflammatory responses [7]. Future research is essential to elucidate the mechanisms by which PRRs operate and to develop targeted therapies that maximize their benefits while minimizing risks. As we advance our understanding of PRRs and their role in immune modulation, new avenues for innovative antiviral and antitumor therapies will likely emerge, offering hope for improved patient outcomes in infectious diseases and cancer.

## 1. Introduction to Pattern Recognition Receptors

Pattern recognition receptors are a diverse group of germline-encoded receptors that play a pivotal role in the innate immune response. PRRs can be classified into several categories, including toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-I-like receptors (RLRs), and C-type lectin receptors (CLRs). These receptors are primarily expressed on immune cells such as macrophages, dendritic cells, and neutrophils, enabling them to detect a wide range of microbial invaders and cellular stress signals[2,3].

Upon recognizing PAMPs or DAMPs, PRRs initiate a cascade of intracellular signaling pathways that lead to the activation of immune responses, including the production of pro-inflammatory cytokines, the upregulation of co-stimulatory molecules, and the maturation of antigen-presenting cells[8]. This activation not only helps clear infections but also shapes the adaptive immune response, thereby playing a crucial role in developing immunological memory.

## 2. Mechanisms of PRR Activation

### 2.1 Toll-Like Receptors (TLRs)

Toll-like receptors are one of the most extensively studied families of PRRs. There are ten known human TLRs (TLR1–TLR10), each with unique ligand specificities and signaling pathways[9]. For example, TLR3 recognizes double-stranded RNA, while TLR7 and TLR8 detect single-stranded RNA viruses. Upon ligand binding, TLRs undergo dimerization and recruit adaptor proteins such as MyD88 or TRIF, leading to the activation of downstream signaling pathways, including NF-κB and MAPK[10]. This process results in the production of inflammatory cytokines such as TNF-α, IL-6, and IL-12, enhancing the innate immune response.

### 2.2 NOD-Like Receptors (NLRs)

NOD-like receptors are cytoplasmic PRRs that recognize intracellular pathogens and stress signals. NLRs, such as NOD1 and NOD2, detect peptidoglycan components from bacterial cell walls, leading to the activation of the NF-κB pathway and the production of pro-inflammatory cytokines [11]. Additionally, some NLRs can form multiprotein complexes known as inflammasomes, which promote the maturation and secretion of IL-1β and IL-18, critical mediators of inflammation and immune responses.

### 2.3 RIG-I-Like Receptors (RLRs)

RIG-I-like receptors are another class of cytoplasmic PRRs that recognize viral RNA. RIG-I and MDA5 are key players in detecting RNA viruses, leading to the activation of type I interferon (IFN) production through the MAVS (mitochondrial antiviral signaling) pathway [12]. This antiviral response not only helps eliminate viral infections but also modulates the adaptive immune response.

### 2.4 C-Type Lectin Receptors (CLRs)

C-type lectin receptors are primarily involved in recognizing carbohydrates on pathogens. They play a vital role in the immune response against fungi and certain bacteria [13]. Upon binding to their ligands, CLRs can activate signaling pathways that enhance the phagocytosis of pathogens and stimulate the production of pro-inflammatory cytokines.

## 3.0 Modulation of Innate Immunity for Antiviral Therapies

Pattern recognition receptors (PRRs) hold significant promise for the development of antiviral therapies. By leveraging their immune-stimulating properties, researchers are investigating various strategies to enhance antiviral responses.

### 3.1 PRR Agonists as Therapeutics

Synthetic PRR agonists, including toll-like receptor (TLR) ligands and RIG-I-like receptor (RLR) activators, can be utilized as adjuvants in vaccine formulations or as standalone therapeutics to strengthen innate immunity against viral infections. For instance, TLR7 and TLR8 agonists have demonstrated efficacy in preclinical studies

and clinical trials by enhancing immune responses to vaccines targeting influenza and other viral pathogens [14]. These agonists stimulate the production of type I interferons and pro-inflammatory cytokines, which are crucial for establishing an effective antiviral response.

### 3.2 Gene Therapy Approaches

Gene therapy approaches that deliver PRR genes into host cells represent a novel strategy for antiviral interventions [15]. This method can induce robust antiviral responses by enhancing the expression of specific PRRs and their downstream signaling components. By increasing the presence of PRRs within the host's cells, the immune system's capacity to recognize and respond to viral threats is significantly amplified. This approach not only offers a direct means of enhancing antiviral immunity but also holds potential for long-term immunological memory, further bolstering the host's defenses against future infections. Overall, the strategic modulation of innate immunity via PRRs offers exciting possibilities for developing innovative antiviral therapies that could improve patient outcomes and enhance the efficacy of existing treatments.

## 4. Modulation of Innate Immunity for Antitumor Therapies

PRRs also play a critical role in the recognition and elimination of tumor cells, offering a pathway for developing effective cancer immunotherapies.

### 4.1 PRR Agonists in Cancer Therapy

PRR agonists can activate innate immune responses that enhance the recognition and destruction of tumor cells. For instance, TLR ligands can stimulate dendritic cells to produce pro-inflammatory cytokines and present tumor antigens to T cells, thereby facilitating the activation of adaptive immunity against tumors [16].

### 4.2 Oncolytic Viruses

Oncolytic viruses, which selectively infect and kill cancer cells, can activate PRRs in the tumor microenvironment, leading to robust innate and adaptive immune responses [17]. This mechanism of action can enhance the therapeutic efficacy of oncolytic virus therapies by promoting tumor-specific immunity.

### 4.3 Combination Immunotherapies

Combining PRR agonists with immune checkpoint inhibitors may improve therapeutic outcomes in cancer treatment. PRR activation can counteract the immunosuppressive tumor microenvironment, enhancing the effectiveness of therapies targeting immune checkpoints such as PD-1 and CTLA-4[18, 19].

## 5. Challenges and Future Perspectives

While the modulation of innate immunity via PRRs holds great promise for antiviral and antitumor therapies, several challenges remain [20, 21]. Understanding the specific mechanisms of PRR activation and signaling in different contexts is crucial for optimizing therapeutic strategies. Additionally, the potential for adverse effects, such as excessive inflammation or autoimmunity, necessitates careful consideration in the development of PRR-targeted therapies [22]. Future research should focus on elucidating the complex interactions between PRRs and various immune cell types, as well as exploring combination therapies that harness the strengths of multiple immunotherapeutic strategies. Advances in drug delivery systems may also enhance the efficacy and safety of PRR-targeted therapies, paving the way for innovative approaches in combating viral infections and cancer [23, 24, 25].

## CONCLUSION

Pattern recognition receptors are essential mediators of innate immunity that play a crucial role in the recognition and response to viral infections and tumorigenesis. Their ability to modulate immune responses offers significant therapeutic potential for antiviral and antitumor therapies. By harnessing the mechanisms of PRR activation, researchers can develop novel immunotherapeutic strategies to enhance immune responses against viral pathogens and cancer. As our understanding of PRRs continues to grow, the translation of these insights into clinical applications may lead to innovative treatments that improve patient outcomes in infectious diseases and cancer.

## REFERENCES

1. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-71. doi: 10.1146/annurev-immunol-031210-101324. PMID: 21219185.
2. Zhao L, Niu J, Feng D, Wang X, Zhang R. Immune functions of pattern recognition receptors in Lepidoptera. Front Immunol. 2023 Jun 16;14:1203061. doi: 10.3389/fimmu.2023.1203061. PMID: 37398667; PMCID: PMC10312389
3. Li D, Wu M. Pattern recognition receptors in health and diseases. Signal Transduct Target Ther. 2021 Aug 4;6(1):291. doi: 10.1038/s41392-021-00687-0. PMID: 34344870; PMCID: PMC8333067.

4. Marongiu L, Gornati L, Artuso I, Zanoni I, Granucci F. Below the surface: The inner lives of TLR4 and TLR9. J Leukoc Biol. 2019 Jul;106(1):147-160. doi: 10.1002/JLB.3MIR1218-483RR. Epub 2019 Mar 22. PMID: 30900780; PMCID: PMC6597292.
5. Rameshbabu S, Labadie BW, Argulian A, Patnaik A. Targeting Innate Immunity in Cancer Therapy. Vaccines (Basel). 2021 Feb 9;9(2):138. doi: 10.3390/vaccines9020138. PMID: 33572196; PMCID: PMC7916062.
6. Ong GH, Lian BSX, Kawasaki T, Kawai T. Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants. Front Cell Infect Microbiol. 2021 Oct 6;11:745016. doi: 10.3389/fcimb.2021.745016. PMID: 34692565; PMCID: PMC8526852.
7. Cao X. Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease. Nat Rev Immunol. 2016 Jan;16(1):35-50. doi: 10.1038/nri.2015.8. PMID: 26711677.
8. Amarante-Mendes GP, Adjemian S, Branco LM, Zanetti LC, Weinlich R, Bortoluci KR. Pattern Recognition Receptors and the Host Cell Death Molecular Machinery. Front Immunol. 2018 Oct 16;9:2379. doi: 10.3389/fimmu.2018.02379. PMID: 30459758; PMCID: PMC6232773.
9. Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014 Sep 25;5:461. doi: 10.3389/fimmu.2014.00461. PMID: 25309543; PMCID: PMC4174766.
10. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A, Flavell RA. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5598-603. doi: 10.1073/pnas.0400937101. Epub 2004 Mar 19. PMID: 15034168; PMCID: PMC397437.
11. Kersse, K., Bertrand, M., Lamkanfi, M., & Vandenabeele, P. (2011). NOD-like receptors and the innate immune system: coping with danger, damage and death.. *Cytokine & growth factor reviews*, *22* 5-6, 257-76 .https://doi.org/10.1016/j.cytogfr.2011.09.003.
12. Yoneyama M, Onomoto K, Jogi M, Akaboshi T, Fujita T. Viral RNA detection by RIG-I-like receptors. Curr Opin Immunol. 2015 Feb;32:48-53. doi: 10.1016/j.coi.2014.12.012. Epub 2015 Jan 14. PMID: 25594890.
13. Shiokawa M, Yamasaki S, Saijo S. C-type lectin receptors in anti-fungal immunity. Curr OpinMicrobiol. 2017 Dec;40:123-130. doi: 10.1016/j.mib.2017.11.004. Epub 2017 Nov 21. PMID: 29169147.
14. Lathrop S, Massena C, Davison C, Schoener R, Burkhart D, Evans J. Co-delivery of antigens with TLR7/8 agonists leads to an improved Th1-mediated immune response to subunit vaccines. The Journal of Immunology. doi.org/10.4049/jimmunol.206.supp.102.09
15. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014 Aug;15(8):541-55. doi: 10.1038/nrg3763. Epub 2014 Jul 15. PMID: 25022906.
16. Klauber TCB, Laursen JM, Zucker D, Brix S, Jensen SS, Andresen TL. Delivery of TLR7 agonist to monocytes and dendritic cells by DCIR targeted liposomes induces robust production of anti-cancer cytokines. Acta Biomater. 2017 Apr 15;53:367-377. doi: 10.1016/j.actbio.2017.01.072. Epub 2017 Jan 30. PMID: 28153581.
17. Cassady KA, Haworth KB, Jackson J, Markert JM, Cripe TP. To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses. Viruses. 2016 Feb 4;8(2):43. doi: 10.3390/v8020043. PMID: 26861381; PMCID: PMC4776198.
18. Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015 Aug;68(2):267-79. doi: 10.1016/j.eururo.2015.02.032. Epub 2015 Mar 29. PMID: 25824720.
19. Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019 Nov 6;18(1):155. doi: 10.1186/s12943-019-1091-2. PMID: 31690319; PMCID: PMC6833286.
20. Rameshbabu S, Labadie BW, Argulian A, Patnaik A. Targeting Innate Immunity in Cancer Therapy. Vaccines (Basel). 2021 Feb 9;9(2):138. doi: 10.3390/vaccines9020138. PMID: 33572196; PMCID: PMC7916062.
21. O' Donovan DH, Mao Y, Mele DA. The Next Generation of Pattern Recognition Receptor Agonists: Improving Response Rates in Cancer Immunotherapy. Curr Med Chem. 2020;27(34):5654-5674. doi: 10.2174/0929867326666190620103105. PMID: 31250749.

22. Lai Y, Dong C. Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int Immunol. 2016 Apr;28(4):181-8. doi: 10.1093/intimm/dxv063. Epub 2015 Nov 6. PMID: 26545932; PMCID: PMC4889878.
23. Moradi Kashkooli F, Soltani M, Souri M. Controlled anti-cancer drug release through advanced nano-drug delivery systems: Static and dynamic targeting strategies. J Control Release. 2020 Nov 10;327:316-349. doi: 10.1016/j.jconrel.2020.08.012. Epub 2020 Aug 12. PMID: 32800878.
24. Kalaydina RV, Bajwa K, Qorri B, Decarlo A, Szewczuk MR. Recent advances in "smart" delivery systems for extended drug release in cancer therapy. Int J Nanomedicine. 2018 Aug 20;13:4727-4745. doi: 10.2147/IJN.S168053. PMID: 30154657; PMCID: PMC6108334.
25. Large D, Soucy J, Hebert J, Auguste D. Advances in Receptor-Mediated, Tumor-Targeted Drug Delivery. Advanced Therapeutics. 2018;2. doi.org/10.1002/adtp.201800091

**CITE AS: Bizimana Rukundo T. (2024). Modulation of Innate Immunity via Pattern Recognition Receptors (PRRs) for Antiviral and Antitumor Therapies. RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 4(1):11-15. https://doi.org/10.59298/RIJBAS/2024/411115**